Treatment News : Gene Therapy for HIV Infection Shows Promise

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » November 2006

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

November 7, 2006

Gene Therapy for HIV Infection Shows Promise
(Reuters Health)

(Reuters Health)—Gene therapy with an HIV-based lentiviral vector can decrease viral loads and increase CD4 T cell counts in chronically infected patients who have failed to respond to at least two antiretroviral regimens, results from a phase I study suggest.

"Gene therapy has long been discussed as an alternative treatment to HIV," senior author Dr. Carl H. June, from the University of Pennsylvania School of Medicine, said in a statement. "The results from this phase I trial are encouraging -- particularly since these are late-stage patients -- and demonstrate that gene therapy has the potential to treat HIV and other serious human diseases."

The open-label, non-randomized trial evaluated the safety and efficacy of VRX496, an HIV-1-derived vector that expresses an antisense sequence against an HIV envelope protein, which prevents viral replication.

Treatment involves transducing a patient's CD4+ T cells with VRX496 and then infusing the cells back into the patient. According to the report in the November 6th early edition of the Proceedings of the National Academy of Sciences, this therapeutic approach was well tolerated and appeared to be safe.

None of the five study patients experienced an increase in viral load and three patients showed a clinical significant reduction in loads at 6 months with no change in their antiretroviral regimen. One subject's viral load decrease was sustained to 36 months. CD4+ T cell counts remained stable or increased in four patients.

"This is an important milestone in the development of what we believe will be the next generation of HIV therapy," Dr. Riku Rautsola, President and CEO of VIRxSYS Corp, the company responsible for VRX496, said in a statement. "VRX496 is engineered in a way that debilitates HIV's ability to replicate and mutate around the therapy, overcoming a common problem with current drug treatments."

To verify the safety of this approach, the researchers will continue to follow the current study group annually for 15 years in accordance with US Food and Drug Administration guidelines. The authors note that two studies are currently underway testing VRX496 at multiple doses.

Proc Natl Acad Sci USA 2006.




Copyright © 2006 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.


[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dambitious
    Gone
    New York


    Newhopenate
    New Hope
    Pennsylvania


    hollywoodvers1
    Los Angeles
    California


    robert12
    Queens
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.